Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #2816794

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
16 850 EUR
16 850 EUR
16 555 EUR
16 555 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for income tax expense
364,000 EUR
2 692 EUR
Adjustments for decrease (increase) in trade accounts receivable
302,000 EUR
Adjustments for increase (decrease) in trade accounts payable
679,000 EUR
Adjustments for depreciation and amortisation expense
1 970 EUR
273,000 EUR
Adjustments for provisions
289,000 EUR
0 EUR
Adjustments for share-based payments
2 944 EUR
1 787 EUR
Cash flows from (used in) operations
10 612 EUR
16 306 EUR
Income taxes paid (refund), classified as operating activities
0 EUR
50,000 EUR
Cash flows from (used in) operating activities
9 919 EUR
19 550 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
827,000 EUR
504,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
265,000 EUR
18 630 EUR
Proceeds from borrowings, classified as financing activities
15 281 EUR
6 960 EUR
Repayments of borrowings, classified as financing activities
40,000 EUR
325,000 EUR
Payments of lease liabilities, classified as financing activities
549,000 EUR
482,000 EUR
Cash flows from (used in) financing activities
14 957 EUR
23 580 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
0 EUR
0 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
4 211 EUR
3 526 EUR
Cash and cash equivalents
33 579 EUR
29 368 EUR
25 842 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.